AIkido Pharma Confirms Receipt of Unsolicited Offer
AIkido Pharma Inc. (Nasdaq: AIKI) announced on August 9, 2022 that it received an unsolicited acquisition offer from Mr. Shalom Auerbach to buy all of its outstanding common stock at $8.00 per share in cash.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIkido Pharma Inc. (Nasdaq: AIKI) announced on August 9, 2022 that it received an unsolicited acquisition offer from Mr. Shalom Auerbach to buy all of its outstanding common stock at $8.00 per share in cash. The Board of Directors will thoroughly evaluate this proposal to determine the best course of action for the company and its shareholders. Shareholders are advised to take no action at this time. AIkido Pharma, established in 1967, is focused on developing small-molecule therapeutics for cancer and viral infections.
Positive
- Received unsolicited acquisition offer of $8.00 per share, indicating potential value increase.
Negative
- No established market for the stock price beyond the offer, creating uncertainty for investors.
Details
News Market Reaction – AIKI
The recorded move for AIKI in the trading session of this news was +1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for
The Company's Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all AIkido shareholders. The Company will respond in due course.
There is no need for shareholders to take any action at this time.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-confirms-receipt-of-unsolicited-offer-301603278.html
SOURCE AIkido Pharma Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.